Gilead Sciences (GILD) EBIT Growth (1y) (2010 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) EBIT Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 32.30% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -520.13% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 8.32% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 19.82% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 145.20% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 10.14% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 1,528.74% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -563.67% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 99.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -520.13% |
| Mar 31, 2026 | 15.60% |
| Dec 31, 2025 | -19.09% |
| Sep 30, 2025 | 274.66% |
| Jun 30, 2025 | -6.43% |
| Mar 31, 2025 | 151.76% |
| Dec 31, 2024 | 52.11% |
| Sep 30, 2024 | -66.15% |
| Jun 30, 2024 | 58.80% |
| Mar 31, 2024 | -353.49% |
| Dec 31, 2023 | -28.89% |
| Sep 30, 2023 | -7.54% |
| Jun 30, 2023 | -17.94% |
| Mar 31, 2023 | 765.48% |
| Dec 31, 2022 | 141.17% |
| Sep 30, 2022 | -26.16% |
| Jun 30, 2022 | -9.66% |
| Mar 31, 2022 | -93.18% |
| Dec 31, 2021 | -64.54% |
| Sep 30, 2021 | 92.00% |